Decreased Rhes mRNA levels in the brain of patients with Parkinson’s disease and MPTP-treated macaques.
PLoS ONE. 2017-07-25; 12(7): e0181677
Read on PubMed
1. PLoS One. 2017 Jul 25;12(7):e0181677. doi: 10.1371/journal.pone.0181677.
Decreased Rhes mRNA levels in the brain of patients with Parkinson’s disease and
Napolitano F(1)(2), Booth Warren E(3), Migliarini S(4), Punzo D(1)(5), Errico
F(1)(2), Li Q(6)(7), Thiolat ML(8)(9), Vescovi AL(10), Calabresi P(11), Bezard
E(6)(7)(8)(9), Morelli M(12)(13), Konradi C(3), Pasqualetti M(4)(14)(15), Usiello
(1)Ceinge Biotecnologie Avanzate, Naples, Italy.
(2)Department of Molecular Medicine and Medical Biotechnology, University of
Naples Federico II, Naples, Italy.
(3)Department of Pharmacology, Vanderbilt University, Nashville, TN, United
States of America.
(4)Department of Biology Unit of Cell and Developmental Biology, University of
Pisa, Pisa, Italy.
(5)Department of Environmental, Biological and Pharmaceutical Sciences and
Technologies, University of Campania, Luigi Vanvitelli, Italy.
(6)Motac Neuroscience, UK-M15 6WE, Manchester, United Kingdom.
(7)Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing,
(8)Université de Bordeaux, Institut des Maladies Neurodégénératives,Bordeaux,
(9)Centre National de la Recherche Scientifique Unité Mixte de Recherche 5293,
Institut des Maladies Neurodégénératives, Bordeaux, France.
(10)IRCSS Casa Sollievo della Sofferenza, ISBReMIT-Institute for Stem Cell
Biology, Regenerative Medicine and Innovative Therapies, San Giovanni Rotondo,
(11)Department of Medicine, University of Perugia and Clinica Neurologica, Santa
Maria della Misericordia Hospital, Perugia, Italy.
(12)National Research Council of Italy (CNR), Neuroscience Institute, Cagliari,
(13)Department of Biomedical Sciences, section of Neuropsychopharmacology,
University of Cagliari, Cagliari, Italy.
(14)Center for Neuroscience and Cognitive Systems, Istituto Italiano di
Tecnologia, Rovereto, TN, Italy.
(15)Neuroscience Institute, National Research Council (CNR), Pisa, Italy.
In rodent and human brains, the small GTP-binding protein Rhes is highly
expressed in virtually all dopaminoceptive striatal GABAergic medium spiny
neurons, as well as in large aspiny cholinergic interneurons, where it is thought
to modulate dopamine-dependent signaling. Consistent with this knowledge, and
considering that dopaminergic neurotransmission is altered in neurological and
psychiatric disorders, here we sought to investigate whether Rhes mRNA expression
is altered in brain regions of patients with Parkinson’s disease (PD),
Schizophrenia (SCZ), and Bipolar Disorder (BD), when compared to healthy controls
(about 200 post-mortem samples). Moreover, we performed the same analysis in the
putamen of non-human primate Macaca Mulatta, lesioned with the neurotoxin
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Overall, our data indicated
comparable Rhes mRNA levels in the brain of patients with SCZ and BD, and their
respective healthy controls. In sharp contrast, the putamen of patients suffering
from PD showed a significant 35% reduction of this transcript, compared to
healthy subjects. Interestingly, in line with observations obtained in humans, we
found 27% decrease in Rhes mRNA levels in the putamen of MPTP-treated primates.
Based on the established inhibitory influence of Rhes on dopamine-related
responses, we hypothesize that its striatal downregulation in PD patients and
animal models of PD might represent an adaptive event of the dopaminergic system
to functionally counteract the reduced nigrostriatal innervation.
PMID: 28742811 [Indexed for MEDLINE]